Patients with SAH with EVDs (n = 26) were prospectively enrolled for the 12 months after implementation of the EVD mobility algorithm and compared with an age- and sex-matched
historical control group from the 12 months before algorithm adoption (n = 19).
The
historical control group did not receive the HFS experience, as it was not a part of the simulation experience, but the group did receive education and training on all clinical skills used in the HFS experience.
The median survival time for the ADXS-HER2 treated dogs was 956 days, which was significantly longer than the 423 day median survival time of the
historical control group.
Results were striking, compared with a
historical control group using telaprevir plus pegylated IFN plus ribavirin, with the threshold for noninferiority and superiority set at 43% , and 54%, respectively.
Comparison was made between the patients in this study and two
historical control groups. The first
historical control group, which was treated with oral placebo in this department, comprised 80 patients [66 (82%) males and 18 (18%) females] with hyphema at a mean age of 14.8 [+ or -] 10.7 years old (range=3-58 years old) with the same race and demographic characteristics.